The Biologics Price Competition and Innovation Act (BPCIA), part of the 2010 Affordable Care Act, sought to drive down prices for biologics, much as the 1984 Hatch-Waxman Act did for small-molecule ...
Despite Uptake Barriers, Real-World Biosimilar Data Demonstrate Safety, Efficacy, Cost-Effectiveness
Presenters explored the real-world evidence in support of biosimilars at the Academy of Managed Care Pharmacy 2024 annual meeting. Biosimilars were a recurring subject at the Academy of Managed Care ...
Biologics are a fast-growing class of therapeutic compounds. In the United States, patent litigation between biologic manufacturers and biosimilar applicants occurs under the Biologics Price ...
Biosimilars offer the potential to deliver substantial cost savings in biologic therapy and to contribute to increased patient access to biologic treatments, both of which are particularly relevant ...
Kayleigh McGlynn, Grant Rice, Ph.D. A biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from an FDA-approved reference biological product.
Integrating biosimilars into health systems pharmacies Biosimilars are reshaping the treatment landscape for biologic-based therapies. In addition to producing clinically-equivalent outcomes to their ...
Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. Biosimilars are gradually making inroads in the outpatient drug ...
Please provide your email address to receive an email when new articles are posted on . The European Union, and specifically Norway, has demonstrated successful strategies for making biosimilars ...
Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. Biosimilars offer clinically effective treatment alternatives to ...
The FDA has approved a new biosimilar drug for inflammatory disease, based on the popular Stelara (ustekinumab). Biosimilar drugs are biologically similar, but not identical to existing biologics. The ...
The lives of more than 10 million Americans — those with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, ulcerative colitis and Crohn’s disease — depend on safe ...
Biosimilars have the potential to offer more affordable treatment options that contribute to the sustainability of our healthcare system. 2 If you haven’t heard of biosimilars, you’re not alone. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results